FDA approves Voceryq, a plasmid-DNA immunotherapy for respiratory papillomatosis

The Food and Drug Administration approved Voceryq on 30 October, the first plasmid-DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP), a rare disease in which benign tumours keep growing back in the airway [s1][s2]. Its formal indication is narrow and precise: it is cleared to reduce the frequency of surgical papilloma excisions in adults with RRP [s2].

That wording matters, because it names the problem RRP patients actually live with. The condition is caused by low-risk human papillomavirus — chiefly HPV-6 and HPV-11 — which seeds wart-like growths on the vocal cords and windpipe. The growths are not cancer, but they recur relentlessly, and the only established treatment is to cut or laser them out, again and again. Some patients undergo dozens of operations over a lifetime to keep their airway open and their voice working. A drug that lowers how often those surgeries are needed addresses the disease exactly where it hurts.

How it works

Voceryq, developed by Inovio Pharmaceuticals, delivers two circular pieces of DNA, called plasmids, into the body's cells [s1]. One carries instructions for making HPV proteins, training the immune system to recognise the virus driving the papillomas; the other encodes interleukin-12, a signalling molecule that amplifies the immune response [s1]. It is given as an intramuscular injection paired with electroporation — brief electrical pulses from a handheld device, the CELLECTRA 5PSP, that help the DNA enter cells [s1][s2].

The regimen is defined. Before the first dose, surgeons debulk the visible papillomas to establish minimal residual disease; the drug is then given at day 0 and weeks 3, 6 and 9 — four doses in all, each 6.25 mg [s2]. It must be administered by a trained healthcare provider using the electroporation device, not self-injected [s2].

The evidence

Efficacy rests on RRP-001 (NCT04398433), an open-label, single-arm study in 32 adults with RRP, all of whom had a history of two or more surgeries to remove laryngotracheal papillomas in the 12 months before enrolment [s2]. There was no comparison group [s2].

The efficacy analysis focused on a sicker subset: the 26 patients who had needed three or more papilloma surgeries in the prior year, a group whose median was 4.5 operations in those 12 months (range 3 to 8) [s2]. The primary endpoint was a complete response, defined as needing no surgical intervention in the 12 months after treatment [s2].

Seven of those 26 patients — 27% (95% CI 12%, 48%) — achieved it, requiring no papilloma surgery across the following year [s2]. The agency notes that going a full year without surgery is not what the disease's natural course would predict in untreated patients who had been operated on that frequently [s1][s2].

Read that figure honestly. A single-arm trial of 26 evaluable patients, measuring each person against their own recent surgical history, is a modest evidence base, and the wide confidence interval — the true response rate could plausibly sit anywhere from 12% to 48% — reflects how few patients were studied. The result is encouraging in a disease with no prior drug option, but it is not a controlled demonstration of benefit against an alternative.

Accelerated, and therefore conditional

Voceryq was cleared under accelerated approval, based on the reduction in surgical excisions as an intermediate endpoint [s1][s2]. Continued approval may depend on confirmatory studies that verify the drug delivers lasting clinical benefit [s2]. As with any accelerated approval, the licence is provisional: it lets patients and surgeons use the therapy now while the obligation to prove its durability remains open.

Safety

The label carries no boxed warning and lists no contraindications [s2]. Its warnings centre on how the drug is given: injection-site reactions, which prompt at least 30 minutes of monitoring after each dose, and electroporation-related effects such as muscle contractions, transient bleeding and fainting [s2]. The device should not be used over extremities with a pacemaker or defibrillator on the same side, metal implants, or skin abnormalities at the treatment site [s2]. The most common adverse reactions, each in more than 5% of patients, were injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness [s2].

What to watch

The open question is durability: whether freedom from surgery in year one holds up over longer follow-up, and whether the three-quarters of patients who did not reach complete response still saw their surgical burden fall. Those answers will come from the confirmatory work the accelerated approval requires. For now, a disease defined by repeat operations has its first drug aimed squarely at reducing them [s2].

Red flags: worsening hoarseness, noisy or difficult breathing, or a sensation of airway blockage in anyone with RRP warrants prompt specialist review rather than waiting. This article describes regulatory news and is not medical advice. Decisions about treatment are for patients and their treating clinicians.